Connect with us

Economics

Enzolytics Inc (OTCMKTS: ENZC) Running Up the Charts After Biotech Outlines Progress and Future Plans (Update on: Artificial Intelligence Diagnostics & ITV-1 and IPF Immune)

Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future plans. The…

Published

on

Enzolytics Inc (OTCMKTS: ENZC) is making an explosive move up the charts after the Company announced a progress update and more on its future plans. The Company spoke in depth of its work at Texas A&M University Institute for Preclinical Studies focused on the production of fully human monoclonal antibodies targeting multiple infectious diseases, including SARS-CoV-2 and HIV-1. Management also outlined the Company’s development of Artificial Intelligence for use in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations.  At Enzolytics’s Dallas laboratory, managed by Harry Zhabilov, the Company’s CSO who coordinates the development and the production of two of the Company’s primary therapeutics, ITV-1 and IPF Immune. Both therapeutics are produced under patents invented by Mr. Zhabilov, U.S. Patent Nos. 8,066,982, 7,479,538, and 8,309,072. ITV-1 is a therapeutic for treating individuals with HIV. It has been successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster. 

ENZC is easily one of the most exciting stocks currently trading on the OTCQB. The stock was one of the biggest runners of 2021 skyrocketing to highs of of $0.958 and now that ENZC has reversed off $0.054 lows speculators are jumping back in and looking for something big here. ENZC has not disappointed so far running hard all day and closing at the high of the day (HOD), a very positive harbinger of things to come. Currently racing northbound, ENZC has huge liquidity, strong momentum and legions of investors from all over the world accumulating at current levels. Microcapdaily first reported on ENZC on September 16, 2020 just as it was taking off northbound after closing at $0.0009 the day before. 

Enzolytics Inc (OTCMKTS: ENZC) is a drug development company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. Enzolytics has been building up a strong Advisory Board to support Enzolytics’ leadership team in achieving the Company’s goals and mission recently adding both Dr. Suraj Kumar Saggar and Dr. Lachezar Bogomilov Ivanov to its Advisory Board. Management is putting a lot of focus on its Intellectual Property portfolio which continues to grow. The focus is on gaining competitive advantage through an aggressive patent strategy. The Company owns patents protecting both ITV-1 and IPF Immune as well as patents in HIV, Coronavirus and a Artificial intelligence platform for use in diagnosing COVID-19. 

One really exciting aspect of ENZC its its Artificial Intelligence platform which is being built under the leadership of Dr. Gaurav Chandra., the Company’s COO. The Healthcare A.I. market is expected to be 34 billion USD in 5 years. Enzolytics A.I. platform is unique because it has been driving the Company’s discoveries and Drug development. A.I. has helped Enzolytics move beyond big pharma’s monoclonal antibody discovery and development. As a result, Enzolytics continues to forge ahead with the immediate strategy to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostics tests, and expand the Company’s Patent portfolio. Enzolytics’ long-term plan is to be a serious contender in the personalized medicine market.  

ITV-1, Enzolytics’s therapeutic for treating individuals with HIV, is being successfully produced and has been earlier successfully clinically tested in human trials under the Bulgarian Drug Agency requirements. The Company has also completed the production of IPF Immune, a product shown to function effectively as an immune booster. Both ITV-1 and IPF are currently in production in accordance the precise methodology and specifications developed by Mr. Zhabilov. IPF Immune will now be available on the U.S. market. The Company IPF Immune dedicated website is expected to premiere this or next week. And the Company expects the product to be available in both large and small retail outlets as well as accessible from the dedicated IPF Immune website. 

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZC

With regard to the anti-HIV therapeutic ITV-1, the Company expects to be able to deploy the therapeutic initially in countries in Africa, followed by completion of EMA certification for use and distribution of the product for therapeutic use throughout Europe. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from sales outside the U.S. 

The Positive Therapeutic Effects of ITV-1 are numerous and include inhibiting the infection of CD4 T-cells by HIV, Reducing HIV viral loads, Replacing or complementing current anti-retroviral therapies. ITV-1 is potentially less costly and much less toxic and may be effective as a periodic therapy instead of a daily one. It is unaffected by HIV mutations that can hamper anti-retroviral therapies (HAART) and tests have shown a 80.5% drop in viral loads. It raises CD4 T-cell counts to healthier levels, a 68% increase in CD4+T-lymphocytes and has good compatibility with other anti-retroviral drugs. ITV-1 has benefits that antiretrovirals do not and may be used in situations where antiretrovirals are not appropriate. 

The Company has engaged Scendea to assist in introducing ITV-1 to EU countries through the EMA and to North America through FDA. Scendea is a leading product development and regulatory consulting group serving the pharmaceutical and biotechnology industry. Scendea’s service will focus on reducing time-to-market and minimizing development costs. Scendea’s team offers strategic and operational support in quality/CMC, non-clinical/toxicology, clinical/medical, and regulatory, guiding the Company’s ITV-1 therapy efficiently to market approval. 

The Company’s IPF Immune therapeutic is now entering the U.S. market. This science-backed immune modulator helps strengthen the body’s defenses against viruses or other pathogens. The product works as an immune booster that increases the ability of the immune system to fight infections by stimulating antiviral activity and helping to increase cell defense. The product supports the body’s immune system thereby enhancing recovery and reducing the recovery period after an illness. The Company is also planning to launch IFP Immune in Europe and Canada. The Company has distributorship contacts in Europe and sees tremendous added potential from foreign sales. This product enters the market as sales of American Dietary Supplements in North American reach $50.11 Billion. These sales are forecast to increase to $77.10 Billion in 2028. Enzolytics has engaged Nutritional Products International (NPI) to access this 50-billion-dollar market=Enzolytics IPF Immune will meet consumer needs due to its significant benefits. 

For more on ENZC Subscribe Right Now!

Currently trading at a $171 million market valuation ENZC has 2,830,435,953 shares outstanding of which 483,789,585 are restricted. For a biotech, the most explosive sector in small caps ENZC has good numbers with $2.23 million in the treasury and manageable debt including some convertibles. ENZC is easily one of the most exciting stocks currently trading on the OTCQB; moving up steadily since reversing off $0.054 lows, ENZC has a history of big moves skyrocketing to highs of $0.958 per share in February 2021 and it still boasts a massive following of investors accumulating at current levels who believe this one is going back up to where it was. While ENZC has gotten cheaper the underlying Company has been busier than ever. Currently ENZC subsidiary Virogentics, is seeing progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries. These toxicology studies will also be used in the Company’s progress toward clinical trials necessary for EMA approval. The ITV-1 therapeutic has succeeded in clinical trials earlier and the Company is planning additional trials leading to EMA approval.  ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy. One of the things that makes Enzolytic’s  ITV-1 stand out from the pack is its safety profile. ITV-1 is really a form of immunotherapy that strengthens the immune system. Most of the HIV drugs are part of the Highly Active Antiretroviral Therapy (HAART) which does its best to use chemotherapy in multiple ways to disrupt the proliferation of the HIV virus. The point to make is all the drug has to do is keep the viral load at bay and the safety profile will be what drives the approval process forward. Don’t underestimate ENZC potential here, it’s a biotech right at 52 week lows, has one of the biggest audiences on the OTCQB, recent highs near $1 and is seeing significant progress with multiple upcoming catalysts in several different billion-dollar sectors.  Microcapdaily first reported on ENZC on September 16 just as it was taking off after closing at $0.0009 the day before. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

The post Enzolytics Inc (OTCMKTS: ENZC) Running Up the Charts After Biotech Outlines Progress and Future Plans (Update on: Artificial Intelligence Diagnostics & ITV-1 and IPF Immune) first appeared on Micro Cap Daily.

Read More

Continue Reading

Economics

Global IT Consulting Sourcing and Procurement Report with Pandemic Impact Analysis, Supplier Evaluation and Price Trends | SpendEdge

Global IT Consulting Sourcing and Procurement Report with Pandemic Impact Analysis, Supplier Evaluation and Price Trends | SpendEdge
PR Newswire
NEW YORK, July 3, 2022

Over 200 Forbes 2000 companies rely on our actionable insightsMore than 100 CPOs…

Published

on

Global IT Consulting Sourcing and Procurement Report with Pandemic Impact Analysis, Supplier Evaluation and Price Trends | SpendEdge

PR Newswire

  • Over 200 Forbes 2000 companies rely on our actionable insights
  • More than 100 CPOs and 500 category managers use our insights daily
  • SpendEdge has the fastest growth rate in number of reports and client base

NEW YORK, July 3, 2022 /PRNewswire/ -- The IT Consulting market size is expected to grow by USD 131.35 Billion by 2025, at a Compound Annual Growth Rate (CAGR) of 9.19% during the forecast period. To know more about this market.

Request For a Free Sample Report

IT Consulting Market Analysis

Analysis of the cost and volume drivers and supply market forecasts in various regions are offered in this IT Consulting research report. This market intelligence report also analyzes the top supply markets, market opportunities, challenges and the critical cost drivers that can aid buyers and suppliers devise a cost-effective category management strategy.

The report provides insights on the following information:

  • Regional spend dynamism and factors impacting costs
  • The total cost of ownership and cost-saving opportunities
  • Supply chain margins and pricing models
  • Competitiveness index for suppliers
  • Market favorability index for suppliers
  • Supplier and buyer KPIs

Get detailed insights on the COVID-19 pandemic crisis and recovery analysis of IT Consulting Market

www.spendedge.com/report/it-consulting-services-market-procurement-research-report

Related Reports on Professional Services Market:

Detect blind spots in your revenue decisions by analyzing interconnected unknowns around the "IT Consulting Market."

Report Metrics

Details

Base year considered

2021

Forecast period

2021 - 2025

Forecast units

USD Billion

Geographies covered

North America, South America, Europe, Middle East and Africa, and APAC

Leading IT Consulting suppliers

Deloitte Touche Tohmatsu Ltd., PricewaterhouseCoopers International Ltd., and Ernst & Young Global Ltd.

Top Pricing Models

Flat-fee model, hourly rate model, and cost-plus model

This procurement report answers help buyers identify and shortlist the most suitable suppliers for their IT Consulting Market requirements following questions:

  • Am I engaging with the right suppliers?
  • Which KPIs should I use to evaluate my incumbent suppliers?
  • Which supplier selection criteria are relevant for?
  • What are the workplace computing devices category essentials in terms of SLAs and RFx?

Table of Content

  • Executive Summary
  • Market Insights
  • Category Pricing Insights
  • Cost-saving Opportunities
  • Best Practices
  • Category Ecosystem
  • Category Management Strategy
  • Category Management Enablers
  • Suppliers Selection
  • Suppliers under Coverage
  • US Market Insights
  • Category scope

Appendix

About SpendEdge:

SpendEdge shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions.

Contact
SpendEdge
Anirban Choudhury
Marketing Manager
Ph No: +1 (872) 206-9340 
https://www.spendedge.com/contact-us

View original content to download multimedia:https://www.prnewswire.com/news-releases/global-it-consulting-sourcing-and-procurement-report-with-pandemic-impact-analysis-supplier-evaluation-and-price-trends--spendedge-301579152.html

SOURCE SpendEdge

Read More

Continue Reading

Spread & Containment

Visualizing A Decade Of Population Growth And Decline In US Counties

Visualizing A Decade Of Population Growth And Decline In US Counties

There are a number of factors that determine how much a region’s population…

Published

on

Visualizing A Decade Of Population Growth And Decline In US Counties

There are a number of factors that determine how much a region’s population changes.

If an area sees a high number of migrants, along with a strong birth rate and low death rate, then its population is bound to increase over time. On the flip side, as Visual Capitalists Nick Routley details below, if more people are leaving the area than coming in, and the region’s birth rate is low, then its population will likely decline.

Which areas in the United States are seeing the most growth, and which places are seeing their populations dwindle?

This map, using data from the U.S. Census Bureau, shows a decade of population movement across U.S. counties, painting a detailed picture of U.S. population growth between 2010 and 2020.

Counties With The Biggest Population Growth from 2010-2020

To calculate population estimates for each county, the U.S. Census Bureau does the following calculations:

      A county’s base population → plus births → minus deaths → plus migration = new population estimate

From 2010 to 2020, Maricopa County in Arizona saw the highest increase in its population estimate. Over a decade, the county gained 753,898 residents. Below are the counties that saw the biggest increases in population:

Phoenix and surrounding areas grew faster than any other major city in the country. The region’s sunny climate and amenities are popular with retirees, but another draw is housing affordability. Families from more expensive markets—California in particular—are moving to the city in droves. This is a trend that spilled over into the pandemic era as more people moved into remote and hybrid work situations.

Texas counties saw a lot of growth as well, with five of the top 10 gainers located in the state of Texas. A big draw for Texas is its relatively affordable housing market. In 2021, average home prices in the state stood at $172,500$53,310 below the national average.

Counties With The Biggest Population Drops from 2010-2020

On the opposite end of the spectrum, here’s a look at the top 10 counties that saw the biggest declines in their populations over the decade:

The largest drops happened in counties along the Great Lakes, including Cook County (which includes the city of Chicago) and Wayne County (which includes the city of Detroit).

For many of these counties, particularly those in America’s “Rust Belt”, population drops over this period were a continuation of decades-long trends. Wayne County is an extreme example of this trend. From 1970 to 2020, the area lost one-third of its population.

U.S. Population Growth in Percentage Terms (2010-2020)

While the map above is great at showing where the greatest number of Americans migrated, it downplays big changes in counties with smaller populations.

For example, McKenzie County in North Dakota, with a 2020 population of just 15,242, was the fastest-growing U.S. county over the past decade. The county’s 138% increase was driven primarily by the Bakken oil boom in the area. High-growth counties in Texas also grew as new sources of energy were extracted in rural areas.

The nation’s counties are evenly divided between population increase and decline, and clear patterns emerge.

Pandemic Population Changes

More recent population changes reflect longer-term trends. During the COVID-19 pandemic, many of the counties that saw the strongest population increases were located in high-growth states like Florida and Texas.

Below are the 20 counties that grew the most from 2020 to 2021.

Many of these counties are located next to large cities, reflecting a shift to the suburbs and larger living spaces. However, as COVID-19 restrictions ease, and the pandemic housing boom tapers off due to rising interest rates, it remains to be seen whether the suburban shift will continue, or if people begin to migrate back to city centers.

Tyler Durden Sat, 07/02/2022 - 21:00

Read More

Continue Reading

Economics

The Best Cities to Buy a Starter Home

Competition for starter homes is intense. What’s a buyer to do? Look to these cities to break into the real estate market.

Published

on

Competition for starter homes is intense. What's a buyer to do? Look to these cities to break into the real estate market.

Who wants to buy a home? A lot more people than there are homes to buy, and the outlook for first-time buyers is particularly grim.

About 26 million Americans plan to buy a home in the next 12 months, but just 5-6 million homes were sold in each of the past five years, according to a NerdWallet survey conducted in December 2021.

Millennials, aged about 26-41 years, are the largest group trying to buy homes, about 37%, according to the National Association of Realtors, and first-time buyers made up 31% of all home buyers. The supply of starter homes decreased by more than half from 2017-2021, according to an analysis by Realtor.com, which defined starters as single-family homes, condos, and townhomes under 1,850 square feet.

While median monthly asking rent in the U.S. surpassed $2,000 in May, the national median sale price topped $431,000, according to Redfin data.

And it’s not just low inventory and high prices, the competition is fierce for first-time homebuyers. Urban renters headed for the suburbs during the pandemic to compete for those entry-level homes, baby boomers looking to downsize also go after smaller properties, and to make matters worse, first-time home buyers must compete with investors who pay cash to fix and flip homes. These cash-rich flippers now make up about 10% of homebuyers

Lastly, builders have largely been unable to offset the decline in starter homes.

For the house hunter who still has the moxie to try, turn to this list of cheapest cities to buy a home. To find the cheapest places for homebuyers and the best places for starter homes, StorageCafe, an online platform that provides storage unit listings across the nation, looked at data from 108 U.S. cities with populations ranging from 90,000 to 8 million. The metrics include property values, number of sales between 2015 and 2021, housing affordability, cost of living, unemployment rate, homebuyers’ ages, the ratio of renters to owners, income levels, FHA lending limits and average mortgage rates. They scored each city on these metrics then ranked them based on their potential with regard to starter homes.

Here are the best cities for first-time homebuyers:

1. Fort Wayne, Ind.

  • Median property value: $113,144
  • Cost of living index: 87
  • Homebuyers' age: 35
  • 2021 average mortgage rate: 3.14%

The analysis used average mortgage rates from 2021, and rates have since gone up, hovering near 6% in June, but last year's rates might still give you a sense of where rates tend to be lower.

2. Columbia Md.

  • Median property value: $264,055
  • Cost of living index:106
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

3. Pittsburgh

  • Median property value: $170,042
  • Cost of living index:104
  • Homebuyers' age: 38
  • 2021 average mortgage rate: 3.03%

Shutterstock

4. Fishers, Ind.

  • Median property value: $258,679
  • Cost of living index: 92
  • Homebuyers' age: 38
  • 2021 average mortgage rate: 3.14%

5. Columbus, Ohio

  • Median property value: $164,229
  • Cost of living index: 92
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.16%

aceshot1 / Shutterstock

6. Carmel, Ind.

  • Median property value: $244,670
  • Cost of living index: 104
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 3.01%

7. St. Paul, Minn.

  • Median property value: $286,151
  • Cost of living index: 92
  • Homebuyers' age: 38
  • 2021 average mortgage rate: 3.14%

8. Cary, N.C.

  • Median property value: $308,611
  • Cost of living index: 94
  • Homebuyers' age: 43
  • 2021 average mortgage rate: 3.02%

9. Manchester, N.H.

  • Median property value: $276,257
  • Cost of living index: 111
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 3.03%

10. Minneapolis

  • Median property value: $288,926
  • Cost of living index: 105
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 3.01%

11. Nashville, Tenn.

  • Median property value: $318,046
  • Cost of living index: 93
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.02%

f11photo / Shutterstock

12. Bakersfield, Calif.

  • Median property value: $216,063
  • Cost of living index: 102
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 3.04%

13. Arvada, Colo.

  • Median property value: $476,672
  • Cost of living index: 114
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

14. Alexandria, Va.

  • Median property value: $432,703
  • Cost of living index: 137
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 2.99%

Shutterstock

15. Centennial, Colo.

  • Median property value: $444,747
  • Cost of living index: 114
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

16. Denver

  • Median property value: $505,777
  • Cost of living index: 113
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

17. Raleigh, N.C.

  • Median property value: $279,304
  • Cost of living index: 94
  • Homebuyers' age: 43
  • 2021 average mortgage rate: 3.02%

18. Germantown, Md.

  • Median property value: $261,511
  • Cost of living index: 157
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

19. St. Petersburg, Fla.

  • Median property value: $283,684
  • Cost of living index: 96
  • Homebuyers' age: 53
  • 2021 average mortgage rate: 3.11%

20. Lakewood, Colo.

  • Median property value: $380,165
  • Cost of living index: 114
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

21. Aurora, Colo.

  • Median property value: $360,542
  • Cost of living index: 114
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.00%

22. Boca Raton, Fla.

  • Median property value: $280,104
  • Cost of living index: 116
  • Homebuyers' age: 51
  • 2021 average mortgage rate: 3.11%

23. Modesto, Calif.

  • Median property value: $319,328
  • Cost of living index: 119
  • Homebuyers' age: 39
  • 2021 average mortgage rate: 3.04%

Shutterstock

24. Chandler, Ariz.

  • Median property value: $388,450
  • Cost of living index: 103
  • Homebuyers' age: 51
  • 2021 average mortgage rate: 3.12%

Shutterstock

25. Las Vegas

  • Median property value: $265,170
  • Cost of living index: 107
  • Homebuyers' age: 50
  • 2021 average mortgage rate: 3.11%

26. Washington, D.C.

  • Median property value: $623,135
  • Cost of living index: 157
  • Homebuyers' age: 40
  • 2021 average mortgage rate: 4.90%

27. Scottsdale, Ariz.

  • Median property value: $478,609
  • Cost of living index: 103
  • Homebuyers' age: 51
  • 2021 average mortgage rate: 3.12%

28. Spokane, Wash.

  • Median property value: $300,881
  • Cost of living index: 107
  • Homebuyers' age: 44
  • 2021 average mortgage rate: 3.06%

29. Peoria, Ariz.

  • Median property value: $373,588
  • Cost of living index: 103
  • Homebuyers' age: 51
  • 2021 average mortgage rate: 3.12%

30. Gilbert, Ariz.

  • Median property value: $409,324
  • Cost of living index: 103
  • Homebuyers' age: 51
  • 2021 average mortgage rate: 3.12%

31. Portland, Ore.

  • Median property value: $484,475
  • Cost of living index: 132
  • Homebuyers' age: 44
  • 2021 average mortgage rate: 3.08%

Check out how all 108 cities ranked and see the methodology for this study at StorageCafe.com

Read More

Continue Reading

Trending